Published time: 02 April 2020
Authors: Stephen W. Mamber, Steven Krakowka, Jeffrey Osborn, Lloyd Saberski, Ryan G. Rhodes, Albert E. Dahlberg, Kara Fitzgerald, Neal Wright, Sarah Beseme, John McMichael
Keywords: COVID-19, SARS-CoV2, Immunomodulators
Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2 or SARS-CoV2) is the cause of the respiratory infection known as COVID-19. From an immunopathological standpoint, coronaviruses such as SARS-CoV2 induce an increase in a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines including interleukins IL-1, IL-6, CCL2 protein and CXCL10 protein. In the absence of proven antiviral agents or an effective vaccine, substances with immunomodulatory activity may be able to inhibit inflammatory and Th1 cytokines and/or yield an anti-inflammatory and/or Th2 immune response to counteract COVID-19 symptoms and severity. This report briefly describes four unconventional but commercially accessible immunomodulatory agents that could be employed in clinical trials to evaluate their effectiveness at alleviating disease symptoms and severity: Low-dose oral interferon-alpha, microdose DNA, low-dose thimerosal and phytocannabinoids.
Could Unconventional Immunomodulatory Agents Help Alleviate COVID19 Symptoms and Severity